<DOC>
	<DOCNO>NCT02061670</DOCNO>
	<brief_summary>The purpose study determine whether safe administer Ragweed-SPIRE subject suffer ragweed allergy asthma .</brief_summary>
	<brief_title>Safety Study Ragweed-SPIRE Subjects With Ragweed Allergies Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Male female , age 1865 year . Asthma treat inhaled SABA inhale SABA plus lowmedium dose ICS 6 week prior randomisation . A reliable history consistent moderate severe rhinoconjunctivitis exposure ragweed least previous two ragweed season . Positive skin prick test ragweed Ragweedspecific Immunoglobulin E ( IgE ) â‰¥ 0.35 kU/L . History lifethreatening asthma . Uncontrolled asthma accord GINA FEV1 &lt; 70 % predict , regardless cause . Administration adrenaline ( epinephrine ) contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . History severe drug allergy anaphylactic reaction food . A history significant disease disorder ( e.g . immune system , pulmonary , cardiovascular , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment , history alcohol drug abuse )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Ragweed</keyword>
	<keyword>Allergy</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>rhinitis</keyword>
	<keyword>asthma</keyword>
</DOC>